Home | Drugs Approvals and Trials

Drugs Approvals and Trials

NIH ends Transcranial Doppler (TCD) with Transfusions Changing to Hydroxyurea (TWiTCH) clinical trial due to early results

What The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has ended the Transcranial Doppler (TCD) with ...

VCU researchers to study vitamin C as treatment for hemorrhagic shock

The Department of Defense has awarded a $1 million grant to Virginia Commonwealth University researchers to test the use of vitamin C ...

NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine

​ Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. ... Full story

Drug for Rare Blood Disorder Developed at Penn Receives Orphan Drug Status from European Union

PHILADELPHIA — A Penn Medicine-developed drug has received orphan status in Europe this week for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis. ... Full story

FDA approves U-M-invented drug for Gaucher disease

ANN ARBOR, Mich. — Cerdelga, a treatment for Gaucher disease type 1 developed at the University of Michigan Medical School and licensed to Genzyme Corp., has been approved by the U.S. Food and Drug Administration. ... Full story

Patient at Royal Manchester Children’s Hospital first to take part in trial of new treatment for rare inherited disease

Researchers at The Royal Manchester Children’s Hospital and The University of Manchester have recruited the first child into a new study, which aims to evaluate the clinical effectiveness of a treatment developed in Manchester. Funded by charity, The Society for Mucopolysaccharide Diseases (The MPS Society)*, the study could alter the lives of patients with Sanfilippo Disease – a fatal inherited condition which causes progressive dementia in children. ... Full story

FDA expands approved use of Imbruvica for chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. ... Full story

Study to investigate whether ibuprofen can reverse the effects of emphysema

Temple University Hospital (TUH) is participating in a nationwide phase II clinical trial that is testing the possibility that ibuprofen can reverse the effects of emphysema. ... Full story

New Technologies Fuel Patient Participation and Data Collection in Research

By Duke Medicine News and Communications - DURHAM, N.C. – The changing dynamic of health studies driven by “big data” research projects will empower patients to become active participants who provide real-time information such as symptoms, side effects and clinical outcomes, according to researchers at Duke Medicine. ... Full story

Vulnerable need pre-trial counselling, say experts

Counsellors need more support to ensure they feel able to give victims of sexual abuse pre-trial counselling, experts will say at an event at The University of Manchester on July 8. ... Full story

1 2 3 4 5 6 7 8 9 10 next last total: 498 | displaying: 1 - 10